Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents

Nature Reviews Cancer

Volumn 10, Issue 4, 2010, Pages 241-253

  Sharma, Sreenath V ^a   Haber, Daniel A ^a   Settleman, Jeff ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DASATINIB; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; FLAVOPIRIDOL; FLUOROURACIL; GEFITINIB; GEMCITABINE; IMATINIB; LAPATINIB; NAVELBINE; NILOTINIB; PACLITAXEL; PANITUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR; ROMIDEPSIN; SORAFENIB; SUNITINIB; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; CANCER CELL CULTURE; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; GASTROINTESTINAL STROMAL TUMOR; GENETIC HETEROGENEITY; GENOMICS; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; NEOPLASM; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; THREE DIMENSIONAL IMAGING; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; MUTATION; NEOPLASMS; PREDICTIVE VALUE OF TESTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 77949957365     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2820     Document Type: Review

References (158)

1. Shoemaker, R. H. The NCI60 human tumour cell line anticancer drug screen. Nature Rev. Cancer 6, 813-823 (2006).
2. Sledge, G. W. Jr, Loehrer, P. J. Sr, Roth, B. J. & Einhorn, L. H. Cisplatin as first-line therapy for metastatic breast cancer. J. Clin. Oncol. 6, 1811-1814 (1988).
3. Bezwoda, W. R., Seymour, L. & Ariad, S. High-dose etoposide in treatment of metastatic breast cancer. Oncology 49, 104-107 (1992).
4. Margolin, K. A. et al. Effective initial therapy of advanced breast cancer with fluorouracil and high-dose, continuous infusion calcium leucovorin. J. Clin. Oncol. 10, 1278-1283 (1992).
5. Gershenson, D. M. et al. A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer. Gynecol. Oncol. 70, 404-409 (1998).
6. Muggia, F. M. et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J. Clin. Oncol. 18, 106-115 (2000).
7. Rossi, A. et al. Single agent vinorelbine as first-line chemotherapy in elderly patients with advanced breast cancer. Anticancer Res. 23, 1657-1664 (2003).
8. Kornblith, P. et al. In vitro responses of ovarian cancers to platinums and taxanes. Anticancer Res. 23, 543-548 (2003).
9. Kornblith, P. et al. Breast cancer\response rates to chemotherapeutic agents studied in vitro. Anticancer Res. 23, 3405-3411 (2003).
10. Kornblith, P. et al. Differential in vitro effects of chemotherapeutic agents on primary cultures of human ovarian carcinoma. Int. J. Gynecol. Cancer 14, 607-615 (2004).
11. Kris, M. G. et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290, 2149-2158 (2003).
12. Fukuoka, M. et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol. 21, 2237-2246 (2003).
13. Cohen, M. H. et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin. Cancer Res. 10, 1212-1218 (2004).
14. Thatcher, N. et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366, 1527-1537 (2005).
15. Shepherd, F. A. et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353, 123-132 (2005).
16. Moore, M. J. et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25, 1960-1966 (2007).
17. Nieto, J., Grossbard, M. L. & Kozuch, P. Metastatic pancreatic cancer 2008: is the glass less empty? Oncologist 13, 562-576 (2008).
18. Saltz, L. B. et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22, 1201-1208 (2004).
19. Vermorken, J. B. et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J. Clin. Oncol. 25, 2171-2177 (2007).
20. William, W. N. Jr, Kim, E. S. & Herbst, R. S. Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck. Nature Clin. Pract Oncol. 6, 132-133 (2009).
21. Van Cutsem, E. et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 25, 1658-1664 (2007).
22. Cobleigh, M. A. et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17, 2639-2648 (1999)
23. Vogel, C. L. et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719-726 (2002).
24. Johnston, S. R. & Leary, A. Lapatinib: a novel EGFR/ HER2 tyrosine kinase inhibitor for cancer. Drugs Today (Barc) 42, 441-453 (2006).
25. + cohort in EGF103009, a phase II study. Lancet Oncol. 10, 581-588 (2009).
26. Escudier, B. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134 (2007).
27. Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008).
28. Motzer, R. J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007).
29. Demetri, G. D. et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368, 1329-1338 (2006).
30. O'Brien, S. G. et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348, 994-1004 (2003).
31. Dagher, R. et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin. Cancer Res. 8, 3034-3038 (2002).
32. Demetri, G. D. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347, 472-480 (2002).
33. Hochhaus, A. et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109, 2303-2309 (2007).
34. le Coutre, P. et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or-intolerant accelerated-phase chronic myelogenous leukemia. Blood 111, 1834-1839 (2008).
35. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002).
36. Weinstein, I. B. Cancer. Addiction to oncogenes\the Achilles heal of cancer. Science 297, 63-64 (2002).
37. Weinstein, I. B. & Joe, A. K. Mechanisms of disease: Oncogene addiction\a rationale for molecular targeting in cancer therapy. Nature Clin. Pract Oncol. 3, 448-457 (2006).
38. Sharma, S. V. et al. A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 10, 425-435 (2006).
39. Sharma, S. V. & Settleman, J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 21, 3214-3231 (2007).
40. Kaelin, W. G. Jr. The concept of synthetic lethality in the context of anticancer therapy. Nature Rev. Cancer 5, 689-698 (2005).
41. Garraway, L. A. & Sellers, W. R. Lineage dependency and lineage-survival oncogenes in human cancer. Nature Rev. Cancer 6, 593-602 (2006).
42. Luo, J., Solimini, N. L. & Elledge, S. J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136, 823-837 (2009).
43. Sharma, S. V., Bell, D. W., Settleman, J. & Haber, D. A. Epidermal growth factor receptor mutations in lung cancer. Nature Rev. Cancer 7, 169-181 (2007).
44. Linardou, H., Dahabreh, I. J., Bafaloukos, D., Kosmidis, P. & Murray, S. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nature Rev. Clin. Oncol. 6, 352-366 (2009).
45. Neve, R. M. et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515-527 (2006).
46. Sos, M. L. et al. Predicting drug susceptibility of nonsmall cell lung cancers based on genetic lesions. J. Clin. Invest. 11 9, 1727-1740 (2009).
47. McDermott, U., Sharma, S. V. & Settleman, J. High-throughput lung cancer cell line screening for genotype-correlated sensitivity to an EGFR kinase inhibitor. Meth. Enzymol. 438, 331-341 (2008).
48. McDermott, U. et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc. Natl Acad. Sci. USA 104, 19936-19941 (2007).
49. McDermott, U. et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res. 68, 3389-3395 (2008).
50. Rodig, S. J. et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin. Cancer Res. 15, 5216-5223 (2009).
51. Shaw, A. T. et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 27, 4247-4253 (2009).
52. McDermott, U. et al. Ligand-dependent platelet-derived growth factor receptor (PDGFR)-α activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. Cancer Res. 69, 3937-3946 (2009).
53. Rikova, K. et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190-1203 (2007).
54. Rosen, J. M. & Jordan, C. T. The increasing complexity of the cancer stem cell paradigm. Science 324, 1670-1673 (2009).
55. Trumpp, A. & Wiestler, O. D. Mechanisms of disease: cancer stem cells\targeting the evil twin. Nature Clin. Pract Oncol. 5, 337-347 (2008).
56. Irish, J. M., Kotecha, N. & Nolan, G. P. Mapping normal and cancer cell signalling networks: towards single-cell proteomics. Nature Rev. Cancer 6, 146-155 (2006).
57. Brock, A., Chang, H. & Huang, S. Non-genetic heterogeneity\a mutation-independent driving force for the somatic evolution of tumours. Nature Rev. Genet. 10, 336-342 (2009).
58. Chen, J., Odenike, O. & Rowley, J. D. Leukaemogenesis: more than mutant genes. Nature Rev. Cancer 10, 23-36 (2010).
59. Lin, W. M. et al. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 68, 664-673 (2008).
60. Finn, R. S. et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 11, R77 (2009).
61. Heiser, L. M. et al. Integrated analysis of breast cancer cell lines reveals unique signaling pathways. Genome Biol. 10, R31 (2009).
62. Mirzoeva, O. K. et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res. 69, 565-572 (2009).
63. Kuo, W. L. et al. A systems analysis of chemosensitivity of breast cancer cells to the polyamine analogue PG-11047. BMC Med. 7, 77 (2009).
64. Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108-112 (2009).
65. Dolma, S., Lessnick, S. L., Hahn, W. C. & Stockwell, B. R. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 3, 285-296 (2003).
66. Luo, J. et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137, 835-848 (2009).
67. Scholl, C. et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137, 821-834 (2009).
68. Yagoda, N. et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 447, 864-868 (2007).
69. Yang, W. S. & Stockwell, B. R. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem. Biol. 15, 234-245 (2008).
70. Borisy, A. A. et al. Systematic discovery of multicomponent therapeutics. Proc. Natl Acad. Sci. USA 100, 7977-7982 (2003).
71. Lehar, J. et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nature Biotechnol. 27, 659-666 (2009).
72. Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043 (2007).
73. Montagut, C. et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 68, 4853-4861 (2008).
74. Drexler, H. G. et al. p53 alterations in human leukemia-lymphoma cell lines: in vitro artifact or prerequisite for cell immortalization? Leukemia 14, 198-206 (2000).
75. Weaver, V. M. et al. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J. Cell Biol. 137, 231-245 (1997).
76. Wang, F. et al. Reciprocal interactions between β1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology. Proc. Natl Acad. Sci. USA 95, 14821-14826 (1998).
77. Jacks, T. & Weinberg, R. A. Taking the study of cancer cell survival to a new dimension. Cell 111, 923-925 (2002).
78. Abbott, A. Cell culture: biology's new dimension. Nature 424, 870-872 (2003).
79. Griffith, L. G. & Swartz, M. A. Capturing complex 3D tissue physiology in vitro. Nature Rev. Mol. Cell Biol. 7, 211-224 (2006).
80. Yamada, K. M. & Cukierman, E. Modeling tissue morphogenesis and cancer in 3D. Cell 130, 601-610 (2007).
81. Wolf, K. et al. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J. Cell Biol. 160, 267-277 (2003).
82. Sahai, E. & Marshall, C. J. Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nature Cell Biol. 5, 711-719 (2003).
83. Friedrich, J., Seidel, C., Ebner, R. & Kunz-Schughart, L. A. Spheroid-based drug screen: considerations and practical approach. Nature Protoc 4, 309-324 (2009).
84. Hollingshead, M. G. et al. In vivo cultivation of tumor cells in hollow fibers. Life Sci. 57, 131-141 (1995).
85. Gorelik, E. et al. Microencapsulated tumor assay: new short-term assay for in vivo evaluation of the effects of anticancer drugs on human tumor cell lines. Cancer Res. 47, 5739-5747 (1987).
86. Lanza, R. P. et al. Xenotransplantation of canine, bovine, and porcine islets in diabetic rats without immunosuppression. Proc. Natl Acad. Sci. USA 88, 11100-11104 (1991).
87. Lacy, P. E., Hegre, O. D., Gerasimidi-Vazeou, A., Gentile, F. T. & Dionne, K. E. Maintenance of normoglycemia in diabetic mice by subcutaneous xenografts of encapsulated islets. Science 254, 1782-1784 (1991).
88. Johnson, J. I. et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 84, 1424-1431 (2001).
89. Decker, S., Hollingshead, M., Bonomi, C. A., Carter, J. P. & Sausville, E. A. The hollow fibre model in cancer drug screening: the NCI experience. Eur. J. Cancer 40, 821-826 (2004).
90. Hall, L. A. et al. The hollow fiber assay: continued characterization with novel approaches. Anticancer Res. 20, 903-911 (2000).
91. Gudjonsson, T., Ronnov-Jessen, L., Villadsen, R., Bissell, M. J. & Petersen, O. W. To create the correct microenvironment: three-dimensional heterotypic collagen assays for human breast epithelial morphogenesis and neoplasia. Methods 30, 247-255 (2003).
92. Nelson, C. M. & Bissell, M. J. Modeling dynamic reciprocity: engineering three-dimensional culture models of breast architecture, function, and neoplastic transformation. Semin. Cancer Biol. 15, 342-352 (2005).
93. Lee, G. Y., Kenny, P. A., Lee, E. H. & Bissell, M. J. Three-dimensional culture models of normal and malignant breast epithelial cells. Nature Methods 4, 359-365 (2007).
94. Friedrich, J., Ebner, R. & Kunz-Schughart, L. A. Experimental anti-tumor therapy in 3-D: spheroids\ old hat or new challenge? Int. J. Radiat. Biol. 83, 849-871 (2007).
95. 213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591). Cancer Res. 61, 2008-2014 (2001).
96. Carlsson, J. & Acker, H. Relations between pH, oxygen partial pressure and growth in cultured cell spheroids. Int. J. Cancer 42, 715-720 (1988).
97. Dubessy, C., Merlin, J. M., Marchal, C. & Guillemin, F. Spheroids in radiobiology and photodynamic therapy. Crit. Rev. Oncol. Hematol. 36, 179-192 (2000).
98. Durand, R. E. & Olive, P. L. Resistance of tumor cells to chemo-and radiotherapy modulated by the three-dimensional architecture of solid tumors and spheroids. Methods Cell Biol. 64, 211-233 (2001).
99. Khaitan, D., Chandna, S., Arya, M. B. & Dwarakanath, B. S. Establishment and characterization of multicellular spheroids from a human glioma cell line; implications for tumor therapy. J. Transl. Med. 4, 12 (2006).
100. Mueller-Klieser, W. Three-dimensional cell cultures: from molecular mechanisms to clinical applications. Am. J. Physiol. 273, C1109-C1123 (1997).
101. Kunz-Schughart, L. A., Freyer, J. P., Hofstaedter, F. & Ebner, R. The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. J. Biomol. Screen 9, 273-285 (2004).
102. Frankel, A., Buckman, R. & Kerbel, R. S. Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res. 57, 2388-2393 (1997).
103. Dit Faute, M. A. et al. Distinctive alterations of invasiveness, drug resistance and cell-cell organization in 3D-cultures of MCF-7, a human breast cancer cell line, and its multidrug resistant variant. Clin. Exp. Metastasis 19, 161-168 (2002).
104. Hazlehurst, L. A., Landowski, T. H. & Dalton, W. S. Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Oncogene 22, 7396-7402 (2003).
105. Serebriiskii, I., Castello-Cros, R., Lamb, A., Golemis, E. A. & Cukierman, E. Fibroblast-derived 3D matrix differentially regulates the growth and drug-responsiveness of human cancer cells. Matrix Biol. 27, 573-585 (2008).
106. David, L. et al. Hyaluronan hydrogel: an appropriate three-dimensional model for evaluation of anticancer drug sensitivity. Acta Biomater 4, 256-263 (2008).
107. Frankel, A., Man, S., Elliott, P., Adams, J. & Kerbel, R. S. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin. Cancer Res. 6, 3719-3728 (2000).
108. Eshleman, J. S. et al. Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res. 62, 7291-7297 (2002).
109. Liu, M. et al. Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer. Cancer Res. 65, 5325-5336 (2005).
110. Howes, A. L. et al. The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. Mol. Cancer Ther. 6, 2505-2514 (2007).
111. Barbone, D., Yang, T. M., Morgan, J. R., Gaudino, G. & Broaddus, V. C. Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids. J. Biol. Chem. 283, 13021-13030 (2008).
112. Friedrich, J. et al. A reliable tool to determine cell viability in complex 3-d culture: the acid phosphatase assay. J. Biomol. Screen 12, 925-937 (2007).
113. Mueller-Klieser, W. Multicellular spheroids. A review on cellular aggregates in cancer research. J. Cancer Res. Clin. Oncol. 11 3, 101-122 (1987).
114. Poland, J. et al. Comparison of protein expression profiles between monolayer and spheroid cell culture of HT-29 cells revealed fragmentation of CK18 in three-dimensional cell culture. Electrophoresis 23, 1174-1184 (2002).
115. Oloumi, A., Lam, W., Banath, J. P. & Olive, P. L. Identification of genes differentially expressed in V79 cells grown as multicell spheroids. Int. J. Radiat. Biol. 78, 483-492 (2002).
116. Dardousis, K. et al. Identification of differentially expressed genes involved in the formation of multicellular tumor spheroids by HT-29 colon carcinoma cells. Mol. Ther. 15, 94-102 (2007).
117. Steel, G. G., Courtenay, V. D. & Peckham, M. J. The response to chemotherapy of a variety of human tumour xenografts. Br. J. Cancer 47, 1-13 (1983).
118. Fiebig, H. H., Maier, A. & Burger, A. M. Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur. J. Cancer 40, 802-820 (2004).
119. Scholz, C. C., Berger, D. P., Winterhalter, B. R., Henss, H. & Fiebig, H. H. Correlation of drug response in patients and in the clonogenic assay with solid human tumour xenografts. Eur. J. Cancer 26, 901-905 (1990).
120. Sausville, E. A. & Feigal, E. Evolving approaches to cancer drug discovery and development at the National Cancer Institute, USA. Ann. Oncol. 10, 1287-1291 (1999).
121. Kelland, L. R. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur. J. Cancer 40, 827-836 (2004).
122. Staquet, M. J., Byar, D. P., Green, S. B. & Rozencweig, M. Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: rationale for a three-stage strategy. Cancer Treat Rep. 67, 753-765 (1983).
123. Suggitt, M. & Bibby, M. C. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin. Cancer Res. 11, 971-981 (2005).
124. Kerbel, R. S. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol. Ther. 2, S134-S139 (2003).
125. Peterson, J. K. & Houghton, P. J. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur. J. Cancer 40, 837-844 (2004).
126. Takimoto, C. H. Why drugs fail: of mice and men revisited. Clin. Cancer Res. 7, 229-230 (2001).
127. Frese, K. K. & Tuveson, D. A. Maximizing mouse cancer models. Nature Rev. Cancer 7, 645-658 (2007).
128. Gopinathan, A. & Tuveson, D. A. The use of GEM models for experimental cancer therapeutics. Dis. Model Mech. 1, 83-86 (2008).
129. Olive, K. P. et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461 (2009).
130. Stinson, S. F. et al. Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen. Anticancer Res. 12, 1035-1053 (1992).
131. Paull, K. D. et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl Cancer Inst. 81, 1088-1092 (1989).
132. Scherf, U. et al. A gene expression database for the molecular pharmacology of cancer. Nature Genet. 24, 236-244 (2000).
133. Weinstein, J. N. et al. Neural computing in cancer drug development: predicting mechanism of action. Science 258, 447-451 (1992).
134. van Osdol, W. W., Myers, T. G., Paull, K. D., Kohn, K. W. & Weinstein, J. N. Use of the Kohonen self-organizing map to study the mechanisms of action of chemotherapeutic agents. J. Natl Cancer Inst. 86, 1853-1859 (1994).
135. Weinstein, J. N. et al. An information-intensive approach to the molecular pharmacology of cancer. Science 275, 343-349 (1997).
136. Alvarez, M. et al. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. J. Clin. Invest. 95, 2205-2214 (1995).
137. Monks, A., Scudiero, D. A., Johnson, G. S., Paull, K. D. & Sausville, E. A. The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets. Anticancer Drug Des. 12, 533-541 (1997).
138. Adams, J. et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59, 2615-2622 (1999).
139. Adams, J. Proteasome inhibition in cancer: development of PS-341. Semin. Oncol. 28, 613-619 (2001).
140. Holbeck, S. L. Update on NCI in vitro drug screen utilities. Eur. J. Cancer 40, 785-793 (2004).
141. Yamori, T. Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics. Cancer Chemother. Pharmacol. 52, S74-S79 (2003).
142. Dan, S. et al. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res. 62, 1139-1147 (2002).
143. Naasani, I., Seimiya, H., Yamori, T. & Tsuruo, T. FJ5002: a potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis. Cancer Res. 59, 4004-4011 (1999).
144. Nakatsu, N. et al. Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays. Mol. Cancer Ther. 4, 399-412 (2005).
145. Yaguchi, S. et al. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J. Natl Cancer Inst. 98, 545-556 (2006).
146. Yamori, T. et al. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel. Cancer Res. 59, 4042-4049 (1999).
147. Shiwa, M. et al. Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the SELDI ProteinChip platform. Biochem. Biophys. Res. Commun. 309, 18-25 (2003).
148. Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566 (2007).
149. Cappuzzo, F. et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J. Clin. Oncol. 27, 1667-1674 (2009).
150. Stephens, P. et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431, 525-526 (2004).
151. Shigematsu, H. et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 65, 1642-1646 (2005).
152. Brose, M. S. et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 62, 6997-7000 (2002).
153. Pratilas, C. A. et al. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res. 68, 9375-9383 (2008).
154. Yamamoto, H. et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res. 68, 6913-6921 (2008).
155. Marks, J. L. et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 68, 5524-5528 (2008).
156. Frei, E. 3rd. The National Cancer Chemotherapy Program. Science 217, 600-606 (1982).
157. Alley, M. C. et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48, 589-601 (1988).
158. Grever, M. R., Schepartz, S. A. & Chabner, B. A. The National Cancer Institute: cancer drug discovery and development program. Semin. Oncol. 19, 622-638 (1992).